scientists are working on extremely-long-performing GLP-1 analogs which will require dosing only once a month or perhaps less often. These extended-release variations could make it even simpler to follow using GLP-1s.  Semaglutide and tirzepatide are now the most well-liked options for weight reduction and type two diabetic issues. Liraglutide st